Antidepressant could be new weapon against shingles pain
NCT ID NCT07361809
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the antidepressant desvenlafaxine can reduce pain from shingles (herpes zoster) better than standard treatments alone. Researchers will enroll 750 adults with moderate to severe pain and compare those taking desvenlafaxine plus usual care to those receiving only usual care. The goal is to see if desvenlafaxine provides additional pain relief without major side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Desvenlafaxine
What this could lead to
If it works, this could offer a new, non-opioid option to ease shingles pain and lower the risk of long-term nerve pain.
What could go wrong
This is an early-stage trial without a specified phase, so results are uncertain. Desvenlafaxine may cause side effects like nausea or dizziness, and it might not provide better pain relief than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tiantan Hospital, Beijing, Beijing 100070
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••